Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Why the Oxford Astrazeneca Vaccine Is Now a Global Gamechanger

11/26/2020 | 10:06am EST

In the long dark tunnel that has been 2020, November stands out as the month that light appeared. Some might see it as a bright light, others as a faint light - but it is unmistakably a light.

On November 9, Pfizer announced the interim results of its candidate vaccine, showing it to be "more than 90% effective" in preventing symptomatic COVID-19 in late-stage human trials. The news was greeted with joy.

A couple of days later, the Russian Direct Investment Fund announced that the candidate vaccine they are funding - dubbed Sputnik V - showed 92% efficacy in late-stage trials. Not to be outdone, Moderna then announced that its candidate vaccine showed 94.5% efficacy.

The latest COVID-19 vaccine announcement comes from Oxford University. And, as with all of the above announcements, it came via press release. Its vaccine candidate, developed in partnership with AstraZeneca, showed an overall effectiveness of 70.4%.

In case that sounds disappointing, bear in mind that these are interim results and the figures might change. Also, the Oxford vaccine was given to one group of volunteers as two standard doses, which showed 62% effectiveness, and another group of volunteers as a smaller dose followed by a standard second dose. This raised effectiveness to 90%.

It's not immediately clear why this is the case. Professor Andrew Pollard, one of the lead researchers on the project, described the results as "intriguing". He also highlighted that the use of lower doses means that there would be more vaccine doses available.

There were no cases of severe COVID-19 in those who received the vaccine. And it seems to generate a protective immune response in older people. Although we'll have to wait for the final breakdown of results to get clarification on that.

Not the only measure

Despite the Oxford vaccine having lower overall effectiveness than the Pfizer or Moderna vaccines - at least at this interim stage - there are other success factors to consider. Safety is one, and the Oxford vaccine is so far reported to have a good safety record with no serious side-effects.

Another crucial factor is storage. The Oxford vaccine can be stored in a domestic fridge. The need for sustained freezing across the whole vaccine journey from factory to clinic at ultra-low temperatures - as seen with the Pfizer vaccine - may be a problem for many countries, but especially poorer countries.

The Oxford vaccine, based on a viral vector, is also cheaper (around US$4) than Pfizer and Moderna's mRNA vaccines - around US$20 and $33, respectively. AstraZeneca has made a "no profit pledge".

Equitable distribution

As I have previously discussed, equitable distribution of new vaccines is vital, especially for low- and middle-income countries which don't have the profile or purchasing power of wealthier countries. GAVI - a global health partnership that aims to increase access to immunisation in poor countries - has worked for years to address this very point. It set up the COVAX initiative in 2020, which has access to 700 million doses of COVID vaccine if clinical trials are successful.

Oxford and AstraZeneca have previously made their own commitments to provide a billion doses of their vaccine for low- and middle-income countries, with a commitment to provide 400 million doses before the end of 2020. Certainly, AstraZeneca has committed to provide more doses to countries outside of Europe and the US than any of its nearest competitors.

An excellent start

These commitments will clearly not be enough for immediate global coverage, but it is an excellent start. Around 9% of the world's population live in extreme poverty, and the health systems around them are fragile. With promises for equitable vaccine distribution, there is hope that the poorer populations around the world will not be forgotten. The global health community must keep its focus on this area.

What does this announcement mean for the world? Potentially a huge amount. But remember that the trials are not yet complete and, at the time of writing, the regulators have yet to approve any of the new vaccine candidates. Even when those hurdles are cleared, we still need to vaccinate the world, which requires successfully navigating the complex obstacles of distance, terrain, politics, cold-chain logistics and human behaviour.

The global pandemic is not over and won't be for a long time yet - but the light is getting brighter.

Michael Head, Senior Research Fellow in Global Health, University of Southampton

Copyright The Conversation Africa. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.71% 7636 Delayed Quote.3.66%
MODERNA, INC. -0.05% 129.65 Delayed Quote.24.10%
PFIZER INC. -0.14% 36.7 Delayed Quote.-0.30%
All news about PFIZER INC.
06:35aDubai airline Emirates offers Pfizer, Sinopharm vaccines to staff
06:06aAP NEWS IN BRIEF AT 6 : 04 a.m. EST
06:06aHow Africa Is Leading From Behind in Global Coronavirus Vaccine Race
05:42aEmirates airline offers COVID-19 vaccines to staff
04:18aCOVID-19 VACCINES : Minister Shandro
03:16aVaccine manufacturing is lumpy, supply not as good as hoped, UK says
02:39aAustralia shares end lower as new COVID-19 cases emerge over weekend
01:20aEU Says Concerned Over Insufficient COVID-19 Doses Expected From BioNTech, Pf..
01:08aPFIZER : Israel trades Pfizer doses for medical data in vaccine blitz
12:48aAustralia shares end lower as fresh COVID-19 cluster emerges in Sydney
More news
Financials (USD)
Sales 2020 48 571 M - -
Net income 2020 17 066 M - -
Net Debt 2020 43 571 M - -
P/E ratio 2020 13,3x
Yield 2020 3,92%
Capitalization 204 B 204 B -
EV / Sales 2020 5,10x
EV / Sales 2021 4,44x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 41,94 $
Last Close Price 36,70 $
Spread / Highest target 44,4%
Spread / Average Target 14,3%
Spread / Lowest Target -1,91%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.30%203 993
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
ABBVIE INC.3.15%195 120